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Objective: Glatiramer acetate (GA), the generic name for Copaxone, an immunomodulatory agent, has
been shown to induce interleukin-1 receptor antagonist (IL-1Ra) production in macrophages. We
therefore tested the effects of GA on the catabolic activities of osteoarthritis (OA) chondrocytes.
Design: Primary human chondrocytes and OA cartilage explants were utilized in this study. IL-1Ra, pro-
matrix metalloproteinase-13 (proMMP-13) and prostaglandin E2 (PGE2) were estimated in the cell
culture supernatants and in vitro MMP-13 activity was measured using ﬂuorogenic substrate. TaqMan
Real-Time quantitative polymerase chain reaction (RT-qPCR) was performed to estimate relative
expression levels of genes.
Results: GA treatment signiﬁcantly increased transcription and production of sIL-1Ra (P¼ 0.001) in both
culture models. Furthermore, addition of GA (100 mg) inhibited: (1) spontaneous collagen degradation as
assayed by CTX II enzyme-linked immunosorbent assay (ELISA) [mean CTX II (ng/g cartilage)] in control
was 7.79 [95% conﬁdence interval (CI) 2.57e13.02]e3.415 (95% CI 0.81e6.02) (P¼ 0.0286); (2) sponta-
neous proMMP-13 secretion [mean MMP-13 (ng/g cartilage)] in control was 16.98 (95% CI 7.739e26.23)
e6.973 (95% CI 1.632e12.31) (P¼ 0.0286); (3) production of IL-1b-induced inﬂammatory mediators such
as nitric oxide (NO) [mean NO (mM)] in IL-1 cultures was 11.47 (95% CI 7.10e15.83)e0.87 (95% CI 0.18
e1.56) (P¼ 0.0022); and (4) recombinant MMP-13 in vitro activity (15e25%; P¼ 0.004).
Conclusions: These data suggest that GA effects may be due to upregulation of IL-1Ra as well as direct
inhibition of MMP-13 activity. Based on these studies, we propose that GA has potential for disease
modifying properties in OA and should be evaluated in vivo in animal studies.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a degenerative joint disease, affecting
more than 27 million people in the United States alone and is the
leading cause of disability in elderly populations1. It is characterized
by a progressive loss of cartilage from articular surfaces of dia-
rthrodial joints. Although its etiology is unknown, hereditary,
developmental, as well as abnormal metabolic and mechanical
processes are all considered to contribute to joint degeneration. The
structure and ultra-structural organization of the cartilage extra-
cellular matrix (ECM) is essential for the maintenance of chon-
drocyte homeostasis and function. In addition to maintaining cell
adhesion, cellematrix interactions regulate responses to growthto: M. Attur, Division of
of Medicine, NYU Hospital for
ork, NY 10003, United States.
ttur).
s Research Society International. Pfactors, cytokines and mechanical stress2. In OA, cell matrix
signaling is disrupted by depletion of collagen and proteoglycan
due to the production of matrix metalloproteinases (MMPs),
aggrecanases (ADAMTSs) and other proteases, resulting in matrix
degradation and the mechanical loss of tissue resilience. Their
production is induced by inﬂammatory cytokines and mediators
such as IL-1b, Tumor necrosis factor-alpha (TNF-a), nitric oxide
(NO), and prostaglandins, which are found at elevated levels in OA
joint tissues3e5.
Interleukin-1 (IL-1b) appears to play a central role in OA path-
ogenesis. Blocking its activity with IL-1 Receptor Antagonist Protein
(IL-1Ra or IRAP) or anti-IL-1 antibodies is a potential therapeutic
approach that will inhibit matrix protease expression and slow
matrix loss4e6. Transgenic mouse studies have demonstrated that
MMP-13, in particular, is a key regulator of cartilage degeneration.
MMP-13-deﬁcient mice are resistant to articular cartilage erosion,
while constitutive overexpression of the protease accelerates
cartilage loss7,8. Therefore, there is an interest in developing
disease-modifying OA drugs (DMOADs) for the treatment of OA,ublished by Elsevier Ltd. All rights reserved.
Table I
MMP-13 secretion and collagen degradation (CTX II fragments) are suppressed by GA in OA cartilage explant cultures
Group CTX II (mg/g cartilage) MMP-13 (ng/g cartilage) sIL-1Ra (ng/g cartilage)
IL-1 (1 ng/ml) GA (mg/ml) Mean (n¼ 4) 95% CI P-value Mean (n¼ 4) 95% CI P-value Mean (n¼ 6) 95% CI P-value
 0 7.80 2.57e13.02  16.98 7.74e26.23  0.50 0.07e0.93 
 10 4.77 2.18e7.35 0.2 7.93 2.54e18.4 0.2 1.14 0.41e2.69 0.485
 50 3.73 0.47e6.98 0.057 4.99 0.56e9.42 0.0286 0.90 0.35e1.46 0.132
 100 3.42 0.81e6.02 0.0286 6.97 1.63e12.31 0.0286 2.86 0.21e5.51 0.065
þ 0 16.07 3.52e28.62  26.55 19.10e34.0  0.82 0.34e1.31 
þ 10 5.06 1.23e8.89 0.0286 17.43 9.55e25.32 0.0571 2.08 0.85e3.30 0.0087
þ 50 3.58 0.98e8.14 0.0286 12.98 5.62e20.34 0.0286 1.62 0.96e2.29 0.026
þ 100 3.73 0.89e6.57 0.0286 11.00 5.76e16.24 0.0286 1.61 0.93e2.30 0.026
Human OA cartilage explant cultures were incubated in serum free Ham’s F-12 medium with GA (5e100 mg/ml) and maintained in basal medium () or stimulated with (þ)
IL-1b (1 ng/ml) stimulation. Explant culture supernatants were analyzed for CTX II fragments (mg/g cartilage) (72 h), proMMP-13 (ng/g cartilage) levels and sIL-1Ra (pg/g
cartilage) after 24 h. The mean and lower and upper limits of 95% CIs are indicated for each condition.
Fig. 1. GA inhibits iNOS and COX-2 protein expression in OA chondrocytes. Human
OA chondrocyte monolayer cultures were incubated with GA in the absence or pres-
ence of IL-1b (10 ng/ml) for 24 h and immuno blot was performed for iNOS and COX-2
protein expression. Of note, iNOS protein levels are suppressed signiﬁcantly by GA
treatments. In contrast, COX-2 proteins levels decreased signiﬁcantly at 100 mg/ml GA
treatments. Percent inhibition of iNOS and COX-2 is shown after normalizing against
b-actin protein.
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degradation.
Recent studies support that bioactive peptides or peptide poly-
mers possess anti-oxidant, anti-cancer, anti-microbial, and anti-
inﬂammatory activities, in addition to having immunomodulatory
effects. These peptides or polymers have 3e20 amino acid residues,
and their activity depends on their amino acid composition and
sequence9e13. Glatiramer acetate (GA) or copolymer1 or Copaxone, is
an immunomodulatory drug currently used in multiple sclerosis
clinics. GA is composed of a mixture of synthetic polypeptides (a
random mix of 50e90 amino acids) composed of four amino acids,
L-glutamic acid (E), L-lysine (K), L-alanine (A), and L-tyrosine (Y) that
are found inmyelin basic protein (MBP)9,14. Themechanism of action
for GA is unknown, although several have been proposed. Adminis-
tration of GA shifts the population of T cells from pro-inﬂammatory
Th1 cells to regulatory Th2 cells that suppress the inﬂammatory
response through the induction of anti-inﬂammatory cytokines such
as IL-109,14. Recently, GA was shown to increase soluble IL-1Ra
(sIL-1Ra) expression in human macrophages/monocytes cells14.
Based on this property, we evaluated the anti-IL-1 effects of GA in
cartilage explant cultures and cultured chondrocytes.
Here we provide evidence that GA reverses IL-1b mediated
degeneration of articular cartilage, via its capacity to induce IL-1Ra
expression and inhibit MMP-13 expression and activity, leading to
decreased collagen degradation. The resultant chondroprotective
effects suggest that GA may have potential as a therapeutic agent
for the treatment of OA.
Materials and methods
Materials
All culture media and fetal bovine serum (FBS) were purchased
from Life Technologies (Gaithersburg, MD, USA). Primary Chon-
drocyte growth media and basal media were purchased from Cell
Applications (San Diego, CA, USA). proMMP-13 and IL-1Ra enzyme-
linked immunosorbent assay (ELISA) kits were purchased from R&D
Systems (Minneapolis, MN, USA). Cell culture media, N-(2-Hydroxy-
ethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES) and TRIzol
were purchased from Invitrogen (Carlsbad, CA, USA). Collagenase P
was purchased from BACHEM Americas Inc. (Torrance, CA, USA). IL-
1b was purchased from PeproTech (Rocky Hill, NJ, USA) and pros-
taglandin E2 (PGE2) ELISA kits from Cayman Chemical Co (Ann
Arbor, MI, USA). carboxy-terminal collagen crosslinks (CTX) II kit
was obtained from Immunodiagnostics (Scottsdale, AZ, USA).
Reagents for real-time quantitative polymerase chain reaction (RT-
qPCR) were from Applied Biosystems (Roster City, CA, USA) and
Clontech laboratories (Mountainview, CA, USA). All antibodies for
Western blot were purchased from BD Biosciences (California, CA,USA). Fluorogenic MMP-13 peptide substrate was purchased from
Peptide International (Louisville, KY, USA).
Procurement of human cartilage
Cartilage slices were obtained from the knees of patients with
advanced OA (age 50e70 years) undergoing knee replacement
surgery. For this study we recruited 20 knee OA patients. A total of
eight cartilage samples were used for ex vivo studies (Table I) and
the remaining 12 samples were used for chondrocyte isolation and
in vitro studies (Fig. 1 and Table IIeIV). All the experiments were
performed either in single or duplicate conditions with atleast
three individual OA patient cartilage or chondrocyte materials. The
use of discarded human cartilage was approved by appropriate
institutional review boards.
Isolation of human chondrocytes
Chondrocytes were obtained from OA cartilage slices by diges-
tion with collagenase P (0.2%) for 12e16 h in Ham’s F-12 medium
containing 10% FBS. This cell suspension was used to establish cell
cultures andmaintained at 37C in a humidiﬁed atmosphere of 95%
air and 5% CO2. Since chondrocytes dedifferentiate after extended
period of monolayer culture, only ﬁrst passage cells were used and
all experiments were performed within 4e6 days of isolation15.
Explant culture of OA cartilage
Brieﬂy, knee articular cartilage from patients undergoing knee
replacement surgerywas obtained. The cartilagewasmixed and cut
into 3-mm discs and 4e6 discs were placed in triplicate or
Table II
GA treatment induces soluble IL-1Ra and inhibits MMP-13 mRNA levels in OA chondrocytes
Group Relative mRNA expression (fold change vs control)
sIL-1Ra MMP-13
IL-1 (10 ng/ml) GA (mg/ml) Mean (n¼ 6) 95% CI P-value Mean (n¼ 7) 95% CI P-value
 0 1.00 1.00e1.01  1.00 1.00e1.01 
 10 5.01 0.99e11.01 0.0649 1.23 0.73e1.73 0.7104
 50 6.48 1.52e11.45 0.0022 0.58 0.30e0.87 0.2620
 100 16.87 9.52e24.23 0.0022 1.09 0.38e1.79 0.2086
þ 0 38.47 9.64e67.29  29.81 7.93e67.54 
þ 5 53.88 15.88e91.87 0.4848 9.35 2.35e21.06 0.1649
þ 10 75.48 25.72e125.20 0.1797 5.67 2.47e13.80 0.0379
þ 50 240.50 8.15e489.20 0.0411 2.56 1.33e6.45 0.0111
þ 100 493.00 37.77e948.20 0.0649 1.69 1.24e4.63 0.0041
Primary OA chondrocytes were incubated with GA (5e100 mg/ml) in the presence and absence of IL-1 (10 ng/ml). The relative fold change of mRNA levels for sIL-1Ra and
MMP-13 over 24 h compared to unstimulated conditions are presented as mean and lower and upper limits of 95% CIs.
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supplemented with 0.2% endotoxin-free human albumin, 10 mM
HEPES at pH 7.4 and antibiotics in the presence of various
modulators15.
Determination of PGE2 and nitrite
PGE2 was determined in the culture supernatant by ELISA, as
reported previously16, with a detection limit of 1.0 pg/ml. NO
production was measured by estimating the stable NO metabolite,
nitrite, in conditioned medium by a modiﬁed Griess reaction17. The
values were expressed as micromolar nitrite or nanograms per
milliliter PGE2 released per g wet weight of cartilage.
RNA extraction from articular chondrocytes
The RNA was extracted directly from monolayer cultures of
chondrocytes using TRIzol. The total RNA was precipitated using
isopropanol and further puriﬁed using micro RNeasy column
(Qiagen, Valencia, CA, USA) as recommended by the manufacturer.
The RNA was estimated using a spectrophotometer. The 260/280
ratio for puriﬁed RNA wasw2.0. The integrity of RNA was checked
using 1% formaldehyde agarose gel electrophoresis.
RT-qPCR
Total RNA (1 mg) was used for cDNA synthesis (Clontech,
Mountainview, CA, USA). TaqMan primer sets were purchased
as predesigned oligonucleotides (GAPDH e Hs99999905_m1;
sIL-1Ra e Hs00174099_m1; icIL-1Ra e Hs00894899_m1; IL-1RII e
Hs00174759_m1; MMP-13 e Hs00233992_m1; iNOS-Hs00167
257_m1 and COX-2 e Hs00153133_m1) from Applied Biosystems.Table III
GA inhibits production of NO and PGE2 in OA chondrocytes
Group Nitrite (mM)
IL-1 (10 ng/ml) GA (mg/ml) Mean (n¼ 6) 95% CI
 0 2.18 1.22e3.14
 10 1.00 0.55e1.45
 50 1.01 0.56e1.45
 100 0.74 0.37e1.11
þ 0 11.47 7.10e15.83
þ 5 6.91 2.24e11.57
þ 10 6.85 1.91e11.78
þ 50 2.21 0.80e3.62
þ 100 0.87 0.18e1.56
Primary OA chondrocytes were incubatedwith GA (5e100 mg/ml) in the presence and abs
post IL-1 treatment. The mean and lower and upper limits of 95% CIs are indicated for eRT-qPCR was run on an Applied Biosystems Prism 7300 sequence
detection system. Messenger RNA levels were normalized using
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a house-
keeping gene, and relative expression levels of various transcripts
were calculated using an approximation method or the 2 delta CT
method18. IL-1Ra expression levels following GA treatment were
normalized to either untreated or IL-1b stimulated control groups
(¼1).
Type II collagen degradation assay
Degradation products of type II collagen were measured using
CTX II based assay kit, according to the instructions of the manu-
facturer (Immunodiagnostics). Values were normalized using wet
weight of cartilage and expressed as microgram fragments released
per gram of cartilage.
ELISA
Primary chondrocytes were treated with GA in triplicate for
indicated times with or without exogenously added IL-1b in serum-
free medium. The conditioned medium was collected after 24 h.
ELISA kits were used to measure secreted sIL-1Ra, proMMP-13 or
PGE2 levels. IL-1Ra, proMMP-13 and PGE2 concentrations were
determined using the respective standard curves according to
manufacturer’s instructions.
Active MMP-13 assay
Brieﬂy, culture supernatant (10e50 ml) was incubated with assay
buffer [50 mM TriseCl (pH 7.5), 10 mM CaCl2, 150 mM NaCl and
0.05%Brij-35] andp-aminophenylmercuric acetate (APMA) for 2 h atPGE2 (ng/ml)
P-value Mean (n¼ 4) 95% CI P-value
 5.09 3.74e6.43
0.0411 3.68 1.03e6.34 0.20
0.026 4.29 3.61e4.96 0.3429
0.0087 2.43 1.85e3.01 0.0286
 85.10 8.65e161.50 
0.0411 13.69 8.30e19.08 0.1143
0.0649 14.81 8.28e21.34 0.1143
0.0022 8.10 4.38e11.81 0.0286
0.0022 6.86 6.17e7.56 0.0286
ence of IL-1 (10 ng/ml). NO and PGE2were estimated in the culture supernatants 24 h
ach condition.
Table IV
GA treatment inhibits iNOS and COX-2 mRNA levels in OA chondrocytes
Group Relative mRNA expression (fold change vs control)
iNOS COX-2
IL-1 (10 ng/ml) GA (mg/ml) Mean (n¼ 7) 95% CI P-value Mean (n¼ 10) 95% CI P-value
 0 1.00 1.00e1.01  1.00 1.00e1.01 
 10 1.42 0.06e2.77 0.2086 0.95 0.37e1.53 0.1431
 50 1.68 0.16e3.20 0.7104 0.67 0.09e1.25 0.0185
 100 1.82 1.94e5.58 0.0262 1.52 0.31e3.36 0.1431
þ 0 234.60 36.72e506.00  67.57 14.83e150.00 
þ 5 199.10 25.77e423.90 0.5350 62.86 33.34e159.10 0.3930
þ 10 101.90 8.66e212.40 0.1649 38.14 13.61e89.89 0.2799
þ 50 69.00 18.91e156.90 0.0728 12.62 1.85e27.09 0.0185
þ 100 53.64 7.02e100.30 0.0973 7.91 0.28e16.09 0.0029
Primary OA chondrocytes were incubated with GA (5e100 mg/ml) in the presence and absence of IL-1b (10 ng/ml). The relative fold change of mRNA levels for iNOS and COX-2
over 24 h compared to unstimulated condition is presented as mean and lower and upper limits of 95% CIs.
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MMP-13 speciﬁc ﬂuorogenic substrate, MOCAc-Pro-Cha-Gly-Nva-
His-Ala-Dap (DNP)-NH2 (Peptide International, Louisville, KY, USA),
and themixture was incubated at 37C. Fluorescence was measured
on a Synergy HT microplate reader at 360/40 nm (excitation) and
460/40 nm (emission) after 1 h. Recombinant proMMP-13 (R&D
Systems) was used as a positive control and standard.In vitro MMP-13 activity
Human recombinant proMMP-13 was used to determine the
effect of GA on MMP-13 activity in vitro. Protease activity was
measured by incubating GA (5e250 mg) with active recombi-
nant MMP-13 (10 ng) 1 h prior to the addition of MMP-13
speciﬁc ﬂuorescence substrate. The relative ﬂuorescence
measured with and without addition of GA was used to
measure the inhibition of enzyme activity. The ﬂuorescent unit
(FU) value of the standard was used for calculating the activity
in the culture samples.Western analysis
Proteins were extracted from monolayer chondrocytes using
M-PER reagent (PIERCE, Rockland, IL, USA). Protein concentrations
were estimated using bicinchoninic acid (BCA) reagent (Pierce) and
20e30 mg total proteins were electrophoresed on sodium dodecyl
sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) gel using
the Bio-Rad electrophoresis system. Proteins were transferred to
nitrocellulose (1 h at 100 V) and blots probed with mouse
cyclooxygenase-2 (COX-2) or inducible nitric oxide synthase (iNOS)
monoclonal antibody (BD Biosciences) and anti-b-actinmonoclonal
antibody (Sigma) to correct for variations in sample loading. The
blots were developed using chemiluminescence system (Amer-
sham). The blots were then scanned and band intensities were
quantiﬁed using UN-SCAN-IT (Silk Scientiﬁc, Inc. Orem, UTAH). The
intensities of the iNOS and COX-2 proteins were normalized to the
housekeeping (internal control) protein b-actin.Proliferation assay
Bromo-deoxy uridine (BrdU) incorporation was used to
compare the proliferation between control and GA-treated chon-
drocytes using BrdU cell proliferation kit (EMD Biosciences). At 24,
48 and 72 h post IL-1b stimulation, the cells were incubated at 37C
overnight with BrdU, as per the manufacturer’s protocol. The cells
were then washed with growth medium and ﬁxed with formalin;
BrdU incorporation was measured spectrophotometrically at450e540 nm. The extent of proliferation was expressed as
absorption unit as compared to unstimulated control.
Statistics
All analysis was performed with atleast 3e7 individual cartilage
or chondrocyte cultures either in single or duplicates. GraphPad
Prism software (ver. 4.0) was used for column statistics to derive
mean and lower and upper 95% CI for each condition. Manne
Whitney test was performed to derive statistical signiﬁcance and
the exact P values are provided.
Results
GA promotes chondroprotective effects in OA cartilage explants
To determinewhether GA is chondroprotective for OA cartilage, we
measured collagen degradation in OA cartilage explants under basal
(serum-free) and IL-1b stimulatedconditions. Consistentwithprevious
reports16,we foundthat IL-1b (1 ng/ml) increased theproductionof the
type II collagen degradation product, CTX II, in culture supernatants
(Table I) approximately 200% compared to untreated controls. Pre-
incubation of OA cartilage with GA (50e100 mg/ml) signiﬁcantly
reversed both spontaneous (P¼ 0.057e0.0286) and IL-1b-mediated
collagen degradation by more than 50e70% (P¼ 0.0286). This effect
was independent of the GA concentration tested. Addition of GA alone
did not interfere with CTX II fragment detection in ELISA. Since MMP-
13 is a major matrix degrading, IL-1b-inducible protease associated
with cartilage degeneration in OA, we also examined its expression
after GA treatment. In explant cultures, GA signiﬁcantly decreased
proMMP-13 secretion w50e80% under basal conditions and
w40e70% in the presence of IL-1b (Table I). Consistent with previous
observations in humanmonocytes, GAalso stimulated sIL-1Ra levels14.
GA treatment increased sIL-1Ra by 200e300% under basal conditions
and 30% in the presence of IL-1b (Table I).
The effects of GA on chondrocyte metabolism were further
investigated using primary cell cultures of OA chondrocytes.
MMP-13 mRNA levels, determined by semi-quantitative PCR, were
suppressed dose dependently under basal conditions and in the
presence of IL-1b (P¼ 0.165e0.0041) following GA treatment
(Table II). For both explant and cell cultures, GA had no effect on
secretion of MMP-1, another major collagenase constitutively
expressed in cartilage (data not shown). GA also signiﬁcantly
induced mRNA levels of sIL-Ra (P¼ 0.0022), in a dose dependent
manner, under basal conditions and moderately in the presence of
IL-1b (Table II). However, GA had no effect on expression the
icIL-1RA isoforms or the soluble IL-1 type II decoy receptor, sIL-1RII
(data not shown).
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or MMP-13 was due to altered cell proliferation we performed
a BrdU proliferation and trypan blue exclusion assay following GA
treatment in the presence and absence of IL-1b. Within the dose
range used in the study (5e100 mg/ml), GA did not affect cell
proliferation or viability (data not shown). Together these data
suggest that GA prevents collagen degradation in OA cartilage via
blockade of IL-1b signaling by up-regulation of sIL-1Ra and inhi-
bition of MMP-13.
GA inhibits NO and PGE2 production in OA chondrocytes
To further demonstrate that GA inhibits the catabolic activity of
OA chondrocytes we measured the effects of GA on the production
of inﬂammatory mediators NO and PGE2. Incubation of OA chon-
drocytes with IL-1b (10 ng/ml) signiﬁcantly induced NO production
from 2.18 to 11.47 mM and PGE2 secretion from 5.09 to 85.10 ng/ml
consistent with previous observations15. Pre-incubation of OA
chondrocyte with GA (5e100 mg/ml) signiﬁcantly inhibited both
spontaneous and IL-1b-induced NO and PGE2 production in a dose-
dependent manner, with the maximum inhibition at 100 mg/ml GA
(Table III). These anti-inﬂammatory effects were further evaluated
bymeasuring mRNA and protein expression levels of inducible NOS
(iNOS), COX-1 and COX-2. As expected, IL-1 treatment alone
signiﬁcantly elevated iNOS and COX-2 mRNA expression levels
(Table IV). Under basal and IL-1b-stimulated conditions GA signiﬁ-
cantly inhibited iNOS expression (Table IV) and this was accompa-
nied by a dose dependent downregulation in protein levels,
detectable by immuno blot (Fig. 1). Conversely, GA mediated
downregulation of COX-2 was only observed upon IL-1 stimulation
at concentrations >50 mg/ml (Table IV). Moreover only a modest
reduction in COX-2 protein level was observed at 100 mg/ml GA
(Fig. 1). Together these ﬁndings suggest that GA inhibits NO via
downregulation of iNOS gene expression while PGE2 may be regu-
lated by both transcriptional and post transcriptional mechanisms.
GA inhibits MMP-13 activity in cartilage explants and can inhibit
enzyme activity directly
The sequence of theGApolymer is comprised of (Glu-Lys-Ala-Tyr
[EKAY]) amino acids in a randommix and shows 20e30% identity to
the CTX-II fragment (EKGPDP amino acid) released upon MMP-13
cleavage at the C-terminus. We thus hypothesized that, in addi-
tion to reducing expression levels, GA can alter MMP-13 activity
directly, by acting as a competitive substrate for the enzyme.
We ﬁrst investigated whether, in addition to suppressing MMP-
13 gene expression levels, the active form of the enzyme is similarly
reduced following GA treatment. OA cartilage cultures were treated
with IL-1b, and supernatants were collected and treated with
APMA to activate proMMP-13. MMP-13 speciﬁc activity was
determined by co-incubation of explant culture supernatants
activated with APMAwith a ﬂuorogenic MMP-13 peptide substrate.
The MMP-13 speciﬁc activity is expressed in FU. Mean MMP-13
speciﬁc activity (FU/g cartilage) in control cultures was 227.8 [95%
CI (lower and upper limits) 206.1e249.5], and this activity
increased signiﬁcantly by more than ﬁve-fold to 1,184 (95% CI
729.8e3,098; P¼ 0.0262) in IL-1b-induced explant culture super-
natants. Preincubation of explant cultures with GA signiﬁcantly
decreased IL-1b induced MMP-13 (FU/g cartilage) activity;
IL-1þGA 10 mg; 195.9 (95% CI 44.5e347.4; P¼ 0.0253); IL-1þGA
50 mg; 216.7 (95% CI 126.8e306.7; P¼ 0.0259) and IL-1þGA
100 mg; 219.8 (95% CI 106e333.2; P¼ 0.0262).
To determine if GA can inhibit MMP activation directly,
recombinant proMMP-13 (10 ng) was APMA-activated and incu-
bated with the ﬂuorogenic substrate in the presence or absence ofGA. Recombinant active MMP-13 (10 ng) yielded mean FU of 106.7
[95% CI (lower and upper limits) 103.8e109.5] enzyme activity. In
GA treatment, the amount of FU is expressed relative to untreated
MMP-13. Pre-incubation of active MMP-13 with GA (5, 10, 50, 100
and 250 mg/ml) inhibited MMP-13 activity in an in vitro assay in
a dose-dependent manner, respectively, as follows: 103.1 (mean
FU) (95% CI 98.18e108.0; P¼ 0.068); 98.88 (95% CI 95.34e102.4;
P¼ 0.048); 90.17 (95% CI 89.41e90.92; P¼ 0.006); 80.00 (95% CI
76.47e83.53; P¼ 0.004); and 75.99 (95% CI 73.34e78.63;
P¼ 0.020). These ﬁndings suggest two possible mechanisms of
MMP-13 inhibition by GA: via downregulation of its expression,
and via direct suppression of enzyme activity by acting as
a competitive substrate.
Discussion
OA pathophysiology is characterized by cartilage breakdown
and production of inﬂammatory mediators. A successful approach
to disease treatment must incorporate restoration of the cartilage
matrix and prevent further cytokine-mediated breakdown. To this
end we investigated the anti-inﬂammatory properties of GA,
a peptide polymer previously shown to block inﬂammation in
multiple sclerosis. We found that GA has the capacity to prevent IL-
1b activity in chondrocytes via upregulation of sIL-1Ra. This led to
complete prevention of IL-1b-mediated collagen degradation in
cartilage explants. Further in vitro analysis suggested that this
chondroprotective effect of GA is elicited by downregulation of
inﬂammatory mediators NO and PGE2 and suppression of MMP-13
gene expression and activity.
The effects of GA were also found to be dose-dependent with
each target molecule and culture condition. However, in most cases
the concentrations needed to achieve signiﬁcant inhibition
(collagen degradation, MMP-13 secretion, NO and PGE2 produc-
tion) were lower in the presence of IL-1b (5e10 mg/ml) compared to
basal (unstimulated) conditions (10e50 mg/ml). This greater
potency suggests that GA selectively inhibits IL-1b signaling.
The role of IL-1b family molecules in OA has beenwidely studied,
and strategies for blocking IL-1b actions are under investigation4e6,15.
We and others have previously shown that addition of IL-1Ra or IL-1
decoy receptor II elicits chondroprotective effects by inhibitingMMP
production15. In clinical studies, anakinra, the recombinant form of
IL-1Ra, has proven to be well tolerated, although in a recent study,
following a single intraarticular injection, IL-1Ra did not show anal-
gesic beneﬁts compared to placebo19. This observation may reﬂect
limitations of recombinant protein administration, where the short
half-life of IL-1Ramay prevent the necessary therapeutic levels of the
protein being reached. This can be overcomeby in vivo or ex vivo gene
delivery, which has shown therapeutic efﬁcacy in several animal
models of inﬂammatory arthritis20e24. As an alternative, agents that
promote endogenous expression of IL-1Ra could potentially avoid
the efﬁcacy and safety concerns associated with exogenous protein
or gene delivery. Interestingly, anti-inﬂammatory agents such as IL-4,
IL-10, TGF-b, IFN-b and COX inhibitor leﬂunomide, were devoid of
any stimulatory effect on sIL-1Ra production by human
chondrocytes25e27. In this regard, induction of sIL-1Ra by GA is
unique to this peptide polymer compound and therefore has
potential advantages for treatment of OA.
Inpatientswithmultiple sclerosis, GAwas found to induce serum
levels of sIL-1Ra. Moreover, in the same study, GA increased T-cell
mediated induction of sIL-1Ra in monocytes14. To date, the mecha-
nism of GA mediated sIL-1Ra induction has not been determined,
although it has been proposed that GA binds to MHC class II antigen
presenting cells leading to a shift of T cell responses toward anti-
inﬂammatory cytokine production28. In the current study we
showed that GA inhibits IL-1b-induced production of NO via
M. Attur et al. / Osteoarthritis and Cartilage 19 (2011) 1158e1164 1163suppression of iNOS gene expression in OA chondrocytes. NO has
been shown to induce cell death and cartilage degeneration4,5,16.
Excessive production of reactive oxygen species and iNOSexpression
in OA chondrocytes trigger cell death and sustain the proin-
ﬂammatory response29,30. In addition, due to the loss of tissue
cellularitywith aging, chondrocytesmay lose the capability to repair
damaged cartilage as a consequence of oxidative stress and other
degradative stimuli31. Thus, GA may be useful in inhibiting proin-
ﬂammatory cytokine-induced oxidative stress in chondrocytes,
thereby protecting cartilage against peroxidation-mediated damage.
GA also inhibited IL-1b-mediated induction of PGE2 indepen-
dent of dose (5e100 mg/ml). However, in contrast to NO and iNOS,
there was no correlationwith COX-2 gene expression, as signiﬁcant
inhibition was only observed at 50e100 mg/ml GA or higher. Simi-
larly, PG synthases cPGES and mPGES, also required for the
generation of PGE2, were not affected by GA treatment (data not
shown). Alternative regulation of COX-2 by GA may occur via
inhibition of enzyme function, as has been described for resveratrol
and NSAIDs such as celecoxib32, although regulation of enzyme
activity was not assessed in the current study.
MMPs are a family of enzymes that are normally required for the
degradation of ECM components, including type II collagen, during
cartilage remodeling33. Recent studies have demonstrated eleva-
tion of MMP-13 in arthritic joints34, and this protease is considered
to be the major MMP responsible for cartilage breakdown7,8. Thus,
blocking MMP-13 activity is a therapeutic approach to OA therapy,
and MMP inhibitors are currently under evaluation as disease
modifying drugs in clinical trials6. Our data indicate that GA
effectively inhibited MMP-13 expression in OA chondrocytes and
cartilage explants stimulated with IL-1b. Our ﬁndings suggest two
modes of inhibition. Since MMP-13 has been shown to be stimu-
lated via IL-1b and PGE2 in OA cartilage16, it is likely that the
inhibitory effect of GA effect occurs via IL-1Ra blockade of IL-1b
signaling. Of possible clinical relevance, GA treatment had no effect
on MMP-1 expression, suggesting its effect is selective for MMP-13.
In this regard, GA is advantageous compared to non-selective MMP
inhibitors, which have demonstrated musculoskeletal side effects
attributed to blockade of MMP-135. An additional level of inhibition
may come via a steric interaction between the enzyme and GA
polymer, preventing its access to the type II collagen substrate. We
propose that this inhibition is due to amino acid homology between
the GA polymer and MMP-13 cleavage site of type II collagen.
Indeed, its sequence homology to MBP is thought to be a mecha-
nism by which GA promotes competition with normal protein for
MHC binding, leading to an alteration in T cell activity in multiple
sclerosis9. However, since GA is composed of a random mix of E, K,
A and Y peptides the precise nature of this interaction is unclear.
Similarly, further studies will be necessary to determine the
mechanism and speciﬁcity of GA binding to MMP-13.
The present ﬁndings suggest a protective role for GA in OA
cartilage, as demonstrated by its ability to prevent IL-1b-mediated
collagen degradation and induction of NO, PGE2 andMMP-13. These
effects are consistent with the biological effects of IL-1Ra, which is
signiﬁcantly elevated by GA treatment under both basal and
inﬂammatory conditions. In vivo studies should determine whether
GA treatment can provide sustained protection of articular cartilage
within an inﬂamedordegenerated joint and thereforebe considered
as an alternative structure-modifying drug for the treatment of OA.
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